Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 6/30/2019 | 3/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 77.1% | 5,778.2% | 238.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 71.7% | 59.8% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -187.3% | -601.9% | -5,586.6% | -245,958.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -400.9% | -575.7% | -6,556.7% | -195,450.4% |
| EPS Diluted | -0.002 | -0.002 | -0 | -0.003 |
| % Growth | -26.7% | -400% | 89.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | $0 | -$0 | -$0 |